IL6 and COVID-19: With initial cases demonstrating remarkable clinical improvements in individuals treated with the anti-interleukin (IL-6) biologic tocilizumab (the standard treatment for CRS), the idea of a CSS in severe COVID-19 became more visible (30, 31).